Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase 3 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Moderate Hepatic Impairment 1Melanoma 1Endometrial Neoplasms 1Chondrosarcoma 1

Interventions

Specimen Handling 51pembrolizumab 46Magnetic Resonance Spectroscopy 38Biopsy 37Cyclophosphamide 34fludarabine 29Cetuximab 20Cisplatin 19Carboplatin 19Radiotherapy 16Bevacizumab 16atezolizumab 15Radiation 15venetoclax 14Nivolumab 14Fluorouracil 14fludarabine phosphate 13Leucovorin 13Gemcitabine 13Temozolomide 11Pemetrexed 11Oxaliplatin 11Cytarabine 11Paclitaxel 10Irinotecan 10Ipilimumab 10130-nm albumin-bound paclitaxel 10Prednisone 9Immunoglobulin G 9Fulvestrant 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × capivasertib × 30 days × Clear all
NCT05039801 2026-06-01

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Recruiting
54 enrolled
DermatologicGynecologicHead & NeckSarcoma

Squamous Cell Carcinoma of Head and Neck, Chondrosarcoma, Melanoma, Ovarian Neoplasms, Endometrial Neoplasms

NCT07343960 2026-05-20

A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

AstraZeneca

Phase 1 Recruiting
20 enrolled

Moderate Hepatic Impairment

Data powered by HemOnc (CC BY 4.0) Colophon âš¡